Biogen vs Gilead Sciences: why the prices moved differently

• ▲

  10 Phase III programs signal growth beyond MS Biogen said it has 10 late-stage trials with results starting in Q4, shifting focus from its shrinking MS business to new drugs like LEQEMBI and ZURZUVAE. This raises hopes for future revenue growth, supporting the stock.

  This is the main new strategic update that could drive long-term growth and investor optimism.

• ▲

  Japan approves at-home Leqembi injection Japan cleared a subcutaneous form of Leqembi, allowing weekly at-home dosing instead of hospital infusions. This is the third country to approve it, making the Alzheimer's drug easier to use and expanding its market, which could boost sales.

  New regulatory approval directly expands the addressable market for a key growth drug.

• ▼

  Medicare price crackdown may limit Zurzuvae launch A study warns that U.S. efforts to align Medicare drug prices with cheaper countries could push companies to raise prices or withdraw medicines elsewhere. Biogen's CEO said Zurzuvae will launch in only a few European countries to offset lost U.S. revenue, signaling a hit to its global sales potential.

  This is a new regulatory risk that could reduce future revenue from a key product.

• ▲

  Biogen posts best quarterly revenue beat in group Biogen's Q2 revenue of $2.74 billion rose 3.4% and beat expectations by 12.1%, the strongest among 11 therapeutics stocks. This shows better-than-expected commercial execution, which can lift investor confidence.

  New earnings data confirms strong performance relative to peers, a positive fundamental signal.

Based on 6 stories →

• ◆

  RayThera acquisition closes, EPS guidance cut Biogen completed its purchase of RayThera, adding an early-stage immunology drug. But acquisition charges forced it to slash 2026 adjusted EPS guidance to $12–$13 from $14.25–$15.25. The revenue outlook rose to mid-single-digit growth, but the profit hit is what investors will feel near-term.

  This is the single biggest new event, directly changing Biogen's earnings outlook and explaining the stock's mixed reaction.

• ▲

  China approves at-home LEQEMBI injection China approved a subcutaneous (under-the-skin) form of LEQEMBI for early Alzheimer's, allowing weekly at-home dosing instead of hospital infusions. This is the second country to clear it, after the U.S. in July. It widens the market and makes treatment far easier for patients.

  A new regulatory approval in a huge market (17 million early Alzheimer's patients in China) directly boosts the long-term sales potential of Biogen's key Alzheimer's drug.

• ▲

  Five Phase 3 readouts ahead; shares seen as undervalued Biogen raised its non-GAAP EPS guidance and has five late-stage trial results coming in lupus, transplant and rare diseases. Shares trade about 10% below the average analyst target, with a 54% one-year total return. But competition in MS and Alzheimer's, plus launch risks for LEQEMBI and ZURZUVAE, remain real concerns.

  This gives the forward-looking catalyst picture and the valuation gap, which is central to why investors are watching Biogen now.

• ▲

  Biogen adopts Veeva's AI-powered CRM globally Biogen selected Veeva's Vault CRM suite, an AI-driven sales and safety platform, for global use. This is an operational upgrade, not a direct revenue driver, but it signals Biogen is investing in modern commercial infrastructure. It also deepens a multi-year software relationship, which can lower long-term selling costs.

  It shows Biogen is modernizing its commercial operations with AI, a modest but real positive for efficiency and execution.

Based on 7 stories →

• ▲

  Q2 beat on rare-disease and Leqembi demand Biogen's second-quarter profit and revenue beat expectations, helped by strong sales of rare-disease medicines and a 15% rise in Leqembi sales to about $184 million. This shows the core business is growing, which supports the stock.

  This is the main new event of the period and directly explains why Biogen is moving.

• ▼

  2026 profit guidance cut on Apellis charges Biogen slashed its 2026 adjusted earnings forecast to $12–$13 per share from $14.25–$15.25, largely due to $3.85 per share of acquisition-related charges, including 85 cents from the $5.6 billion Apellis buyout. This weighs on the stock.

  This is the key counterweight that explains why the stock isn't rising more despite the earnings beat.

• ▲

  Leqembi real-world data and sales momentum A real-world study showed over 75% of early Alzheimer's patients remained stable on Leqembi, and Q2 sales grew 43% excluding one-time stockpiling. This supports adoption and future sales, a positive for Biogen as Eisai's partner.

  This new evidence reinforces the commercial case for Biogen's key Alzheimer's drug.

• ▲

  Pipeline progress: Gazyva priority review, litifilimab enrollment The FDA granted priority review to Gazyva for a rare kidney disease, and Biogen's lupus drug litifilimab completed Phase III enrollment with results due in H2 2026. These advance the pipeline and offer future growth, supporting the stock.

  These are new regulatory and clinical milestones that add to the long-term growth story.

Based on 12 stories →

• ▲

  FDA approves at-home subcutaneous Leqembi The FDA approved Leqembi Iqlik, a once-weekly under-the-skin injection for early Alzheimer's, allowing at-home dosing. This removes the need for IV infusions, which should boost patient demand and sales. Biogen shares rose on the news.

  This is a major new approval that directly expands the market for Biogen's key Alzheimer's drug.

• ▲

  Diranersen shows 42% cognitive decline slowdown Biogen presented Phase 2 data showing its tau-targeting drug diranersen slowed cognitive decline by 42% on one measure and cut tau tangles. This suggests a potential new Alzheimer's treatment, lifting hopes for future growth.

  Positive efficacy data from a new drug candidate is a key driver of investor optimism.

• ▼

  Dosing paradox clouds diranersen data, stock tumbles The same Phase 2 trial missed its main goal because the lowest dose worked best while higher doses did worse. This unexplained 'dosing paradox' raised doubts about the drug's effectiveness and path forward, causing Biogen shares to fall nearly 9%.

  This negative twist directly caused a sharp sell-off and creates uncertainty about a key pipeline asset.

• ▲

  Truist upgrade highlights Alzheimer's pipeline A Truist analyst upgrade pointed to optimism for Biogen's Alzheimer's pipeline, helping the stock gain even as the broader market fell. This analyst view reinforced positive sentiment around the company's Alzheimer's efforts.

  Analyst upgrade is a fresh catalyst that supported the stock price during the period.

Based on 7 stories →

• ▲

  RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.

  This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.

• ▲

  FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.

  This is a new regulatory win that supports the bull case for Biogen's pipeline.

• ▼

  Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.

  This is a new negative event that introduces regulatory and legal uncertainty.

• ▼

  Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.

  This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

Based on 6 stories →

• ▲

  Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

  This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

• ▲

  PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

  This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

• ▲

  Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

  Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

• ▲

  Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

  Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

Based on 6 stories →

• ▲

  HIV sales growth guidance raised to 9–10% Gilead lifted its full-year HIV sales growth outlook to 9–10% from 8%, citing a $4 billion annualized PrEP business and strong Biktarvy. Higher expected sales mean more profit, which supports a higher stock price.

  This is a direct, new upgrade to the company's core revenue outlook, a key driver of the stock.

• ▲

  FDA approves Bixlenvo, a new single-tablet HIV regimen The FDA approved Bixlenvo, a once-daily single tablet for complex HIV cases. It is the smallest such option and the first for patients who cannot take existing single-tablet therapies, opening a new market and reinforcing Gilead's HIV leadership.

  A new product approval expands the addressable market and future revenue, directly lifting growth prospects.

• ▲

  European Commission expands Trodelvy approval in first-line TNBC The EC approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making it the only antibody-drug conjugate plus immunotherapy combo in that setting across the EU. This widens oncology sales and diversifies revenue beyond HIV.

  A major regulatory win in a new indication that boosts the oncology franchise and long-term growth.

• ▲

  Pipeline expands with MacroGenics option and once-weekly HIV data Gilead exercised an option on a MacroGenics bispecific cancer program, and positive Phase 3 results for a once-weekly oral HIV regimen with Merck were announced. These add future growth options, though they are early and not yet near-term revenue.

  New pipeline additions signal longer-term growth potential, which can support a higher valuation.

Based on 6 stories →

• ▲

  Q2 revenue beat and raised full-year guidance Gilead reported Q2 revenue of $7.8 billion, up 10% and above estimates, and raised 2026 product sales guidance to $29.8–$30.1 billion. HIV sales rose 12% to $5.7 billion, with Biktarvy up 7%. This shows the core business is growing faster than expected, which supports a higher stock price.

  This is the period's central event and directly explains the positive fundamental momentum behind GILD.

• ▲

  PrEP franchise tops $1 billion; Yeztugo persistence strong Quarterly PrEP sales doubled year-over-year to over $1 billion for the first time, led by the twice-yearly shot Yeztugo ($232 million, up 40% from Q1). Over 70% of patients stayed on Yeztugo after a year, the best among PrEP options. This growing prevention business adds a new revenue stream and reduces reliance on HIV treatment alone.

  It highlights a key new growth driver that is boosting investor confidence and future sales.

• ▼

  Large acquisition charges push reported EPS deeply negative Gilead's Q2 GAAP EPS was a loss of $8.45, and non-GAAP EPS was a loss of $6.75, due to $11.2 billion in acquired IPR&D expenses from buying Arcellx, Tubulis, and Ouro Medicines. Excluding these one-time charges, EPS would be $8.50–$8.85. The headline loss may scare some investors, but it is an accounting effect, not a cash drain on operations.

  It is the main counterweight in the period and explains why reported earnings look bad despite strong operations.

• ▲

  Analyst reiterates Buy; pipeline advances in oncology and HIV BofA reiterated a Buy rating and $162 price target, citing Yeztugo's persistence and raised guidance. Separately, European regulators backed Trodelvy plus Keytruda for first-line triple-negative breast cancer, and a once-weekly oral HIV regimen with Merck met its Phase 3 goals. These expand future sales opportunities.

  It shows external validation and pipeline progress that support the stock's longer-term growth story.

Based on 8 stories →

• ▲

  Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

  This is a new strategic update that shows Gilead's growth beyond its core HIV business.

• ▲

  Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

  This is a new clinical milestone that could lead to a new product and boost future sales.

• ▲

  CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

  This is a new regulatory step that could lead to approval and broader use of a key drug.

• ▲

  Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

  This is a new potential use for an existing drug, but the financial impact is not yet clear.

Based on 6 stories →

• ▲

  FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

  This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

• ▲

  FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

  This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

• ▲

  Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

  New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

• ▼

  Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

  This is a new negative financial disclosure that could cap upside from the positive pipeline news.

Based on 7 stories →